1. Cyhoeddwyd

   HTAs and rare diseases: How to assess their cost-effectiveness

   Hughes, D., Phillips, C. J. & Hughes, D. A., 1 Tach 2011, Yn: Pharmaceuticals Policy and Law. 13, 3-4, t. 161-165

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

2. Cyhoeddwyd

   Have infection control and prevention measures resulted in any adverse outcomes for care home and domiciliary care residents and staff? Report number: RR_00018 (November 2021)

   Spencer, L., Hartfiel, N., Hendry, A., Anthony, B., Makanjuola, A., Bray, N., Hughes, D., Wilkinson, C., Fitzsimmons, D. & Edwards, R. T., 1 Tach 2021, 36 t.

   Allbwn ymchwil: Llyfr/Adroddiad › Adoddiad Arall › adolygiad gan gymheiriaid

3. Cyhoeddwyd

   Health Economics Analysis Plans: Where Are We Now?

   Thorn, J., Ridyard, C., Hughes, D., Wordsworth, S., Mihaylova, B., Noble, S. & Hollingworth, W., 3 Tach 2016, t. A397. 1 t.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Murlen › adolygiad gan gymheiriaid

4. Cyhoeddwyd

   Health and economic outcomes: Why compliance matters

   Hughes, D. & Hughes, D. A., 1 Ebr 2006.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

5. Cyhoeddwyd

   Health economic aspects of patient non-compliance

   Hughes, D., Hughes, D. A., Davies, M. (gol.) & Kermani, F. (gol.), 1 Ion 2006, Patient Compliance: Sweetening the Pill. 2006 gol. Gower Publishing, t. 23-40

   Allbwn ymchwil: Pennod mewn Llyfr/Adroddiad/Trafodion Cynhadledd › Pennod

6. Cyhoeddwyd

   Health economics analysis plans: the current state of play

   Thorn, J., Ridyard, C., Hughes, D., Wordsworth, S., Mihaylova, B., Noble, S. & Hollingworth, W., 7 Mai 2017, t. P144. 1 t.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Murlen › adolygiad gan gymheiriaid

7. Cyhoeddwyd

   Health utilities and costs for Motor Neurone Disease

   Moore, A., Young, C. A. & Hughes, D., Tach 2019, Yn: Value in Health. 22, 11, t. 1257-1265

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

8. Cyhoeddwyd

   Health utilities and costs for neuromyelitis optica spectrum disorder

   Hughes, D., Bourke, S., Jones, A., Bhatt, R., Huda, S., Mutch, K. & Jacob, A., 2022, Yn: Orphanet Journal of Rare Diseases. 17, 11 t., 159.

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

9. Cyhoeddwyd

   Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving reldesemtiv or placebo in FORTITUDE-ALS

   Gebrehiwet, P., Meng, L., Saroccoa, P., Wei, J., Wolff, A. A., Butzner, M., Chio, A., Andrews, J. A., Genge, A., Hughes, D., Jackson, C. E., Lechtzin, N., Miller, T. M. & Shefner, J. M., 31 Maw 2023, Yn: Journal of Medical Economics. 26, 1, t. 488-493 6 t.

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

10. Cyhoeddwyd

    Identification Of Items For A Standardised Resource-Use Measure: Review Of Current Instruments

    Thorn, J. C., Ridyard, C., Riley, R., Brookes, S., Hughes, D., Wordsworth, S., Noble, S. & Hollingworth, W., Tach 2015.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur › adolygiad gan gymheiriaid

11. Cyhoeddwyd

    Identification and Assessment of Adherence-Enhancing Interventions in Studies Assessing Medication Adherence Through Electronically Compiled Drug Dosing Histories: A Systematic Literature Review and Meta-Analysis

    Hughes, D., Holmes, E. A., Demonceau, J., Ruppar, T., Kristano, P., Hughes, A. D., Fargher, E., Przemyslaw, K., De Geest, S., Dobbels, F., Lewek, P., Urquhart, J. & Vrijens, B., 1 Mai 2013, Yn: Drugs. 73, 6, t. 545-562

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

12. Cyhoeddwyd

    Impact of Interventions on Medication Adherence and Blood Pressure Control in Patients with Essential Hypertension: A Systematic Review by the ISPOR Medication Adherence and Persistence Special Interest Group

    Hughes, D., Gwadry-Sridhar, F. H., Manias, E., Lal, L., Salas, M., Hughes, D. A., Ratzki-Leewing, A. & Grubisic, M., 1 Gorff 2013, Yn: Value in Health. 16, 5, t. 863-871

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

13. Cyhoeddwyd

    Impact of non-adherence and flare resolution on the cost effectiveness of treatments for gout: Application of a linked pharmacometric/pharmacoeconomic model

    Hill-McManus, D., Marshall, S., Soto, E., Lane, S. & Hughes, D., Rhag 2018, Yn: Value in Health. 21, 12, t. 1373-1381

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

14. Cyhoeddwyd

    Impact of non-adherence on the safety and efficacy of uric acid lowering therapies in the treatment of gout

    Hill McManus, D., Soto, E., Marshall, S., Lane, S. & Hughes, D., Ion 2018, Yn: British Journal of Clinical Pharmacology. 84, 1, t. 142-152

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

15. Cyhoeddwyd

    Impact of non-compliance on the clinical and cost-effectiveness of statins

    Hughes, D. & Hughes, D. A., 1 Tach 2001.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

16. Cyhoeddwyd

    Impact of non-compliance on the cost-effectiveness of pharmaceuticals

    Hughes, D. & Hughes, D. A., 1 Tach 2002.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

17. Cyhoeddwyd

    Impact of non-compliance on the cost-effectiveness of statin therapy

    Hughes, D., Hughes, D. A. & Bagust, A., 1 Medi 2001, Yn: Value in Health. 4, 6, t. 489

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

18. Cyhoeddwyd

    Impact of non-compliance on the therapeutic coverage of oxybutynin – comparison of once- and twice-daily oral formulations.

    Hughes, D. & Hughes, D. A., 1 Ion 2002, 2002 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

19. Cyhoeddwyd

    Impact of non-compliance on the therapeutic coverage of risperidone – comparison of long acting injectible with oral formulations.

    Hughes, D. & Hughes, D. A., 1 Ion 2002, 2002 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

20. Cyhoeddwyd

    Impact of pharmacogenetics on the costs of managing adverse events with warfarin: A prospective analysis.

    Hughes, D., Hughes, D. A., Al-Zubiedi, S., Hanson, A., Jorgensen, A. & Pirmohamed, M., 1 Ion 2009.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

21. Cyhoeddwyd

    Impact of relaxing Covid-19 social distancing measures on rural North Wales: a simulation analysis

    Hughes, R. P. & Hughes, D., 14 Rhag 2020, Yn: Frontiers in Public Health. 8, 562473.

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

22. Cyhoeddwyd

    Impact of the abolition of prescription charges in Wales: a multi-level modelling approach with application to time series dispensed rate data

    Hughes, D., Alam, F., Myles, S., Hughes, D. A., Dunstan, F., Routledge, P. & Cohen, D., 1 Medi 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

23. Cyhoeddwyd

    Impact of the abolition of the prescription charge in Wales

    Hughes, D. & Hughes, D. A., 1 Tach 2008.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

24. Cyhoeddwyd

    Impact of the abolition of the prescription charge in Wales.

    Hughes, D., Hughes, D. A., Alam, M. F., Cohen, D., Dunstan, F., Groves, S. & Routledge, P., 1 Ion 2009.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

25. Cyhoeddwyd

    Impact of the abolition of the prescription charge in Wales.

    Hughes, D., Hughes, D. A., Alam, M. F., Cohen, D., Dunstan, F., Groves, S. & Routledge, P., 1 Ion 2009, t. O41.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur